Effective April 1, 2018:
Incidence of hypoglycemia in adult patients withT2DM treated with SOLIQUA 100/33
NO CLINICALLY IMPORTANT DIFFERENCESIN RISK OF SEVERE AND DOCUMENTED SYMPTOMATIC HYPOGLYCEMIA BETWEEN SOLIQUA 100/33 AND COMPARATORS WERE OBSERVED IN CLINICAL TRIALS*
*The hypoglycemia rates in these clinical trials may not be representative of hypoglycemia rates that occur in actual clinical practice.
†Severe symptomatic hypoglycemia defined as an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.
‡Documented symptomatic hypoglycemia defined as an event with typical symptoms of hypoglycemia accompanied by a self-monitored plasma glucose value equal to or less than 70 mg/dL.
DISCONTINUATION DUE TO GI EVENTS IN CLINICAL TRIALS: 1.1%2
§ Gastrointestinal adverse reactions occur more frequently at the beginning of therapy.1